Drug interactions
Empagliflozin-linagliptin + Fosamprenavir
Severity: Moderate
Empagliflozin-linagliptin and Fosamprenavir: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Protease inhibitors such as amprenavir, the active form of fosamprenavir, may cause insulin resistance and hyperglycemia, which can reduce the effectiveness of antidiabetic therapy. Fosamprenavir also has CYP3A4 effects that may modestly change linagliptin levels.
What this interaction means in plain words
Empagliflozin-linagliptin and Fosamprenavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Protease inhibitor-associated insulin resistance opposes antihyperglycemic action; CYP3A4 modulation may alter linagliptin exposure.
What to do
Monitor blood glucose and HbA1c during therapy and adjust the antidiabetic regimen as needed.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Fosamprenavir, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Frequently asked questions
Can I take Empagliflozin-linagliptin with Fosamprenavir?
MediHelp rates the interaction as moderate. Empagliflozin-linagliptin and Fosamprenavir can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Protease inhibitors such as amprenavir, the active form of fosamprenavir, may cause insulin resistance and hyperglycemia, which can reduce the effectiveness of antidiabetic therapy. Fosamprenavir also has CYP3A4 effects that may modestly change linagliptin levels.
How serious is the interaction between Empagliflozin-linagliptin and Fosamprenavir?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose and HbA1c during therapy and adjust the antidiabetic regimen as needed.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
